Artiva Biotherapeutics Shares Fall After Announcing Plan to End AlloNK Development, Analyst Downgrades

02:51 PM EDT, 10/27/2026 (MT Newswires) -- Artiva Biotherapeutics (ARTV) shares fell 31% in Tuesday afternoon trading after the drugmaker said it will discontinue further development of AlloNK, its cell therapy candidate being assessed in combination with rituximab in rheumatoid arthritis and other B-cell-driven autoimmune diseases. Wedbush downgraded the stock to neutral from outperform and lowered its price target to $4 from $40, while Needham downgraded the stock to hold from buy. Artiva's decision follows a review of the overall risk-benefit based on updated clinical data, including longer-term follow-up and recent Grade 5 safety events, the company said. Artiva said it is also reducing its workforce and evaluating options, including a merger or sale, to maximize stockholder value. Price: 4.25, Change: -1.91, Percent Change: -31.01